Allergan Aesthetics unveils new AA Signature Program and immersive booth at IMCAS World Congress 2025
Allergan Aesthetics, an AbbVie company, announces the launch of its new AA Signature Program at IMCAS World Congress 2025 in Paris. The program offers a personalized approach to aesthetic treatment planning, focusing on lift, definition, and skin quality improvements.
Research indicates that 80% of patients proceed with treatments following holistic consultations, and clinics using multi-area treatment plans see a 68% higher retention rate. The congress will feature an AMI symposium with live injection demonstrations, expert presentations, and an interactive exhibition booth.
The event includes a Medical Symposium on 'Mastering the Lower Face and Neck' and Meet the Experts sessions featuring renowned professionals like Dr. Jean Carruthers, who pioneered the cosmetic use of neuromodulators. The Allergan Aesthetics booth (E130, Level 1) will serve as a discovery hub for the new program and product portfolio.
Allergan Aesthetics, una società di AbbVie, annuncia il lancio del suo nuovo AA Signature Program al congresso mondiale IMCAS 2025 a Parigi. Il programma offre un approccio personalizzato alla pianificazione dei trattamenti estetici, concentrandosi su sollevamenti, definizione e miglioramenti della qualità della pelle.
Le ricerche indicano che l'80% dei pazienti prosegue con i trattamenti dopo consultazioni olistiche, e le cliniche che utilizzano piani di trattamento multi-area mostrano un 68% di tasso di fidelizzazione in più. Il congresso includerà un simposio AMI con dimostrazioni di iniezioni dal vivo, presentazioni di esperti e uno stand espositivo interattivo.
L'evento prevede un Simposio Medico su 'Dominare il Volto Inferiore e il Collo' e sessioni 'Incontra gli Esperti' con professionisti rinomati come il Dr. Jean Carruthers, che ha aperto la strada all'uso cosmetico dei neuromodulatori. Lo stand di Allergan Aesthetics (E130, Livello 1) fungerà da hub di scoperta per il nuovo programma e il portafoglio prodotti.
Allergan Aesthetics, una empresa de AbbVie, anuncia el lanzamiento de su nuevo AA Signature Program en el Congreso Mundial IMCAS 2025 en París. El programa ofrece un enfoque personalizado para la planificación de tratamientos estéticos, centrándose en el levantamiento, la definición y la mejora de la calidad de la piel.
La investigación indica que el 80% de los pacientes continúa con los tratamientos tras consultas holísticas, y las clínicas que utilizan planes de tratamiento multiárea tienen una tasa de retención un 68% más alta. El congreso contará con un simposio AMI con demostraciones de inyecciones en vivo, presentaciones de expertos y un stand de exhibición interactivo.
El evento incluye un Simposio Médico sobre 'Dominando la Parte Inferior de la Cara y el Cuello' y sesiones de Encuentro con los Expertos con profesionales reconocidos como el Dr. Jean Carruthers, quien fue pionero en el uso cosmético de neuromoduladores. El stand de Allergan Aesthetics (E130, Nivel 1) servirá como un centro de descubrimiento para el nuevo programa y el portafolio de productos.
알레르간 미용(Aesthetics)은 애브비(AbbVie) 소속으로, 2025년 파리에서 열리는 IMCAS 세계 congress에서 새로운 AA Signature Program의 출범을 발표합니다. 이 프로그램은 리프팅, 정의, 피부 품질 개선에 초점을 맞춰 개인화된 미용 치료 계획을 제공합니다.
연구 결과에 따르면 환자의 80%가 총체적인 상담 후 치료를 진행합니다. 다중 영역 치료 계획을 사용하는 클리닉은 68% 더 높은 유지율을 보입니다. 이번 congress에서는 실시간 주입 시연, 전문가 발표 및 인터랙티브 전시 부스가 있는 AMI 심포지움이 열릴 것입니다.
이 행사는 '하부 얼굴과 목을 마스터하기'에 관한 의료 심포지움과 유명 전문가인 Dr. Jean Carruthers와의 전문가 세션을 포함하고 있습니다. 알레르간 미용 부스(E130, 1층)는 새로운 프로그램과 제품 포트폴리오에 대한 발견 허브 역할을 할 것입니다.
Allergan Aesthetics, une entreprise d'AbbVie, annonce le lancement de son nouveau AA Signature Program lors du Congrès Mondial IMCAS 2025 à Paris. Le programme propose une approche personnalisée pour la planification des traitements esthétiques, en se concentrant sur le lifting, la définition et l'amélioration de la qualité de la peau.
La recherche indique que 80 % des patients poursuivent les traitements suite à des consultations holistiques, et les cliniques utilisant des plans de traitement multi-zones affichent un taux de fidélisation supérieur de 68 %. Le congrès comprendra un symposium AMI avec des démonstrations d'injection en direct, des présentations d'experts et un stand d'exposition interactif.
L'événement inclut un Symposium Médical sur 'Maîtriser le Visage Inférieur et le Cou', ainsi que des séances 'Rencontrez les Experts' mettant en vedette des professionnels renommés comme le Dr Jean Carruthers, qui a été pionnier dans l'utilisation cosmétique des neuromodulateurs. Le stand d'Allergan Aesthetics (E130, Niveau 1) sera un centre de découverte pour le nouveau programme et le portefeuille de produits.
Allergan Aesthetics, ein Unternehmen von AbbVie, kündigt die Einführung seines neuen AA Signature Program beim IMCAS World Congress 2025 in Paris an. Das Programm bietet einen personalisierten Ansatz für die ästhetische Behandlungsplanung, der sich auf Hebung, Definition und Verbesserung der Hautqualität konzentriert.
Forschungsergebnisse zeigen, dass 80 % der Patienten nach ganzheitlichen Beratungsgesprächen mit Behandlungen fortfahren, und Kliniken, die Multibereichsbehandlungspläne verwenden, weisen eine 68 % höhere Bindungsrate auf. Der Kongress wird ein AMI-Symposium mit Live-Injektionsdemonstrationen, Expertenpräsentationen und einem interaktiven Ausstellungsstand umfassen.
Die Veranstaltung beinhaltet ein medizinisches Symposium zum Thema 'Mastering the Lower Face and Neck' sowie die Sessions 'Meet the Experts' mit renommierten Fachleuten wie Dr. Jean Carruthers, der die kosmetische Verwendung von Neuromodulatoren maßgeblich vorangetrieben hat. Der Stand von Allergan Aesthetics (E130, Ebene 1) wird als Entdeckungszentrum für das neue Programm und das Produktportfolio dienen.
- 80% patient conversion rate following holistic consultations
- 68% higher patient retention rate with multi-area treatment plans
- Launch of new personalized treatment planning program
- None.
- New AA (Allergan Aesthetics) Signature Program provides a personalized approach to treatment planning, in combination with Allergan Aesthetics' advanced facial portfolio to address patient needs and treat different areas of the face
- Expert led Allergan Medical Institute (AMI) symposium will demonstrate how to elevate the patient experience and achieve optimal treatment outcomes using AA Signature program looks
- The Allergan Aesthetics booth offers an immersive experience where healthcare professionals can learn about the product portfolio, the enhanced customer experience and evolution of the AMI Digital World learning platform
Research found that 8 in 10 patients proceed with treatment plans following a holistic consultation1 and clinics utilizing treatment plans addressing multiple areas of the face see a
IMCAS 2025 AMI Symposium
The AMI hosted symposium, 'AA Signatures: Innovating the Patient Journey', will focus on how to design a patient's signature look using the Allergan Aesthetics portfolio of high-quality products, education and support services, through real world examples from experts. A live injection session will be performed from the Allergan Center of Excellence in Italy and will focus specifically on 'lift' from the AA Signature Program, which addresses research finding that sagginess is one of the most undesirable facial features.3
Date/Time | Location | Speakers |
Saturday, February 1, 2025 10:30 AM – 12:30 PM CET | Grand Amphi, Level 1 | • Dr. Anna Hoo ( • Prof. Dr. Dario Bertossi ( • Dr. Juliana Chieppe ( • Prof. Dr. Reha Yavuzer ( |
Allergan Aesthetics Medical Symposium Mastering the Lower Face and Neck
On Friday January 31, 2025, Dr. Alexandre Marchac, Dr. Karim Sayed, Dr. Patricia Ogilvie and Dr. Sylwia Lipko-Godlewska will spotlight research and the clinical experience needed to achieve optimal patient outcomes during a panel discussion titled 'Mastering the Lower Face and Neck' which will take place from 08:30 AM – 10:00 AM CET in Room 252, Level 2.
With 1 in 2 people bothered by lines / wrinkles around the lower face4, this year's Medical Symposium on 'Mastering the Lower Face and Neck' offers HCPs the support and expertise needed to streamline operations, deepen knowledge and ultimately help advance towards aesthetic excellence in this area.
Meet the Experts
The Meet the Experts sessions on the booth will feature renowned medical professionals, including, Dr. Jean Carruthers who is globally recognized for her pivotal role in the development of today's aesthetic industry. Dr. Jean Carruthers co-wrote the first published paper on the cosmetic use of neuromodulators in 1992 in the Journal of Dermatologic Surgery and Oncology. Dr. Jean Carruthers is credited with discovering the cosmetic use of neuromodulators, which led to the launch of the first neuromodulator in aesthetic medicine: BOTOX® Cosmetic from Allergan Aesthetics.
Title | Provider |
Why is Vistabel® at the core and future of aesthetic | Dr. Jean Carruthers ( |
Shining light on Juvéderm®: The relevance of | Dr. Babak Esfahani ( |
Skin quality treatments in concert: What is the role of | Dr. Carole Woodward ( |
Refine and define: Elevating aesthetics with | Dr. Ligia Colucci ( |
Allergan Aesthetics Booth E130, Level 1
The booth will be a discovery hub for exploring the new AA Signature Program, where visitors can get hands-on familiarity with the Allergan Aesthetics portfolio and immerse themselves in the product experience, including: exploring unique product rheology, learning about innovative technologies and practicing injection technique with the guidance of clinical specialists. To continue learning, visitors can join AMI Digital World and access world class education on demand.
Notes to Editors
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter), and YouTube
About Allergan Aesthetics
At Allergan Aesthetics, an AbbVie company, we develop, manufacture, and market a portfolio of leading aesthetics brands and products. Our aesthetics portfolio includes facial injectables, body contouring, plastics, skin care, and more. Our goal is to consistently provide our customers with innovation, education, exceptional service, and a commitment to excellence, all with a personal touch. For more information, visit www.allerganaesthetics.com
Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2023 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
IMPORTANT SAFETY INFORMATION
BOTOX® Cosmetic may cause serious side effects that can be life threatening. Get medical help right away if you have any of these problems any time (hours to weeks) after injection of BOTOX® Cosmetic:
- Problems swallowing, speaking, or breathing, due to weakening of associated muscles, which can be severe and result in loss of life. You are at the highest risk if these problems are preexisting before injection. Swallowing problems may last for several months.
- Spread of toxin effects. The effect of botulinum toxin may affect areas away from the injection site and cause serious symptoms, including loss of strength and all-over muscle weakness, double vision, blurred vision and drooping eyelids, hoarseness or change or loss of voice, trouble saying words clearly, loss of bladder control, trouble breathing, and trouble swallowing.
BOTOX® Cosmetic dosing units are not the same as, or comparable to, any other botulinum toxin product.
There has not been a confirmed serious case of spread of toxin effect when BOTOX® Cosmetic has been used at the recommended dose to treat frown lines, crow's feet lines, forehead lines, and/or platysma bands.
BOTOX® Cosmetic may cause loss of strength or general muscle weakness, vision problems, or dizziness within hours to weeks of receiving BOTOX® Cosmetic. If this happens, do not drive a car, operate machinery, or do other dangerous activities.
Serious and/or immediate allergic reactions have been reported, including itching, rash, red itchy welts, wheezing, asthma symptoms, or dizziness or feeling faint. Get medical help right away if you are wheezing or have asthma symptoms, or if you become dizzy or faint.
Do not receive BOTOX® Cosmetic if you are allergic to any of the ingredients in BOTOX® Cosmetic (see Medication Guide for ingredients); had an allergic reaction to any other botulinum toxin product such as Myobloc (rimabotulinumtoxinB), Dysport (abobotulinumtoxinA), Xeomin (incobotulinumtoxinA), Jeuveau (prabotulinumtoxinA-xvfs), Daxxify (daxibotulinumtoxinA-lanm), or Letybo (letibotulinumtoxinA-wlbg); or have a skin infection at the planned injection site. This list may not include all available botulinum toxin products.
Tell your doctor about all your muscle or nerve conditions, such as ALS or Lou Gehrig's disease, myasthenia gravis, or Lambert-Eaton syndrome, as you may be at increased risk of serious side effects, including difficulty swallowing and difficulty breathing, from standard doses of BOTOX® Cosmetic.
Tell your doctor about all your medical conditions, including surgery or plans to have surgery on your face, trouble raising your eyebrows, drooping eyelids, any other abnormal facial change, are pregnant or plan to become pregnant (it is not known if BOTOX® Cosmetic can harm your unborn baby), or are breastfeeding or plan to (it is not known if BOTOX® Cosmetic passes into breast milk).
Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Using BOTOX® Cosmetic with certain other medicines may cause serious side effects. Do not start any new medicines until you have told your doctor that you have received BOTOX® Cosmetic in the past.
Tell your doctor if you have received any other botulinum toxin product in the last 4 months; have received injections of botulinum toxin such as Myobloc, Dysport, Xeomin, Jeuveau, Daxxify, or Letybo in the past (tell your doctor exactly which product you received); have recently received an antibiotic by injection; take muscle relaxants; take an allergy or cold medicine; take a sleep medicine; or take aspirin-like products or blood thinners.
Other side effects of BOTOX® Cosmetic include dry mouth; discomfort or pain at the injection site; tiredness; headache; neck pain; and eye problems, including double vision, blurred vision, decreased eyesight, drooping eyelids and eyebrows, swelling of eyelids, and dry eyes.
Approved Uses
BOTOX® Cosmetic is a prescription medicine that is injected into muscles and used to temporarily improve the look of moderate to severe forehead lines, crow's feet lines, frown lines between the eyebrows, and vertical bands connecting the jaw and neck (platysma bands) in adults.
For more information, refer to the Medication Guide or talk with your doctor.
To report a side effect, please call Allergan Aesthetics at 1-800-678-1605.
Please see BOTOX® Cosmetic full Product Information, including Boxed Warning and Medication Guide.
Global Media: | Investor Relations: |
Michael Salzillo | Liz Shea |
Adelle Infante | |
*AA Signature, by Allergan Aesthetics, is a new program that is launching Internationally at the IMCAS congress in
References:
- Allergan Aesthetics. Data on Ule. REF-115016. HCP Facial Injectables ATU: Neurotoxins—Final Report. January 2022.
- Humphrey S et al. J Cosmet Dermatol. 2021;20:1495–1498.
- Allergan Aesthetics. Data on File. The Lower Face Customer & HCP Journey: Qualitative Research Report. May 2024
- Allergan Aesthetics. Data on File. RES-215748. Consumer and MD Beauty Global Image Research (UD 360 report lower face data). 2019.
View original content to download multimedia:https://www.prnewswire.com/news-releases/allergan-aesthetics-unveils-new-aa-signature-program-and-immersive-booth-at-imcas-world-congress-2025-302359301.html
SOURCE AbbVie
FAQ
What is Allergan Aesthetics' new AA Signature Program announced at IMCAS 2025?
What are the key statistics supporting ABBV's new aesthetic treatment approach?
When and where will ABBV's Allergan Aesthetics present at IMCAS World Congress 2025?
What are the main focus areas of ABBV's new AA Signature Program?
